We Can Help You Plan Your Nonclinical Toxicology Studies

Every successful development program begins with informed decisions. Nonclinical toxicology studies provide the safety data needed to evaluate risk, support regulatory submissions, and advance promising therapies toward the clinic. Complete the form to connect with our experts and discuss the right strategy for your program.

Scientist wearing safety goggles and gloves uses a pipette to transfer liquid in a laboratory.

Toxicology Is Complex. Your Quote Doesn’t Have to Be.

Designing a safety assessment program starts with several crucial decisions, including species selection, study sequencing, regulatory expectations, and budgeting.

Share where you are, and we’ll help define what’s needed to move forward with clarity.

  • ✓ Scientific input before you commit to a quote
  • ✓ Program design tailored to your molecule or modality
  • ✓ GLP and non-GLP studies aligned to your timeline and budget
  • ✓ Regulatory expertise supporting IND, CTA, NDA, and global submissions
  • ✓ Full programs or stand-alone studies, based on your needs

1,500+

IND programs conducted annually

8,500+

GLP studies executed each year

> 95%

on-time reporting

PCR samples ready for testing.

Your Guide to General Toxicology
This eBook outlines our general toxicology services while sharing challenges and advantages with Charles River conducting your general toxicology services.
Download the eBook

Scientist in a laboratory wearing safety goggles and gloves examines a test tube containing a yellow liquid.

Integrated Toxicology in Practice
Explore how integrated toxicology strategies support smarter safety decisions across development, helping teams reduce risk and anticipate regulatory expectations in this on-demand webinar.
Watch the webinar

 Illustration of neurons

Exploratory Toxicology for Neuroscience Drug Discovery
This eBook describes strategies across the early stages of drug discovery to support confidence in your lead small molecule candidate and to ensure you proceed through the drug development process with the most promising candidate.
Download the eBook

I have been nothing but extremely satisfied: that includes excellence of the expertise, quality of the interactions, proactivity to solve issues and keep up with the timelines. I would definitely work again with them and highly recommend them to anyone looking for these types of services.”

Hélène Sicard, Director, Research and Drug Development, Representing an established, well-funded French Biotech company, Paris, Île-de-France 

Connect With Us Today